Skip to main content

Paradigm Genetics Reports Fallen Q1 Revenue as Net Loss Narrows

NEW YORK, May 1 - Paradigm Genetics today reported a decline in first-quarter revenue atop receded R&D spending and narrowed net losses.


The ag-genomics company said total revenue for the period ended March 31 fell to $4.1 million from $5.6 million during the same time last year. Income from commercial partnerships in the first quarter 2003 shrank to $3.8 million from $5.6 million year over year, though Paradigm was able to book $228,000 in grant revenue in the quarter.


R&D spending also decreased, to $5.8 million in the current first quarter from $7.6 million for the same time one year ago, according to Paradigm. Included in these numbers was $71,000 and $105,000 in stock-based compensation in the 2003 and 2002 periods, respectively.


Net loss fell to $4.1 million, or $.13 per share, from $5.2 million, or $.16 per share, year over year, Paradigm said.


The company had roughly $11 million in cash, cash equivalents, and short-term investments as of March 31.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.